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Purpose: To analyze the paired box gene 6 (PAX6) in Korean patients with congenital aniridia.
Methods: Genomic DNA was isolated from peripheral blood leukocytes of 22 aniridia patients in 18 unrelated families.
Polymerase chain reaction was performed for all 14 exons of PAX6 followed by bidirectional sequencing.
Results: Fourteen different kinds of mutations were detected in 16 of 18 unrelated families (mutation detection rate:
88.9%), including four novel mutations; c.658G>T (p.Glu220*), c.464delG (p.Ser155Thrfs*52), c.87_90dupTGTA
(p.Glu31Cysfs*26), and c.642A>C (p.Arg214Ser), among which the former three mutations induce premature termination
of PAX6 protein translation. Approximately 92.9% of identified mutations lead to the premature termination of the protein
resulting from 7 nonsense mutations (50.0%), 3 splicing errors (21.4%), 2 deletions (14.3%), and 1 insertion (7.1%).
Conclusions: Most of the mutations identified in Korean aniridia patients lead to the premature truncation of the PAX6
protein, supporting that PAX6 protein haploinsufficiency causes the classic aniridia phenotype. We also found four novel
PAX6 mutations associated with aniridia.
Congenital  aniridia  (OMIM  106210)  is  a  rare  ocular
malformation that affects the development of multiple ocular
structures and is caused by a mutation in the paired box gene
6 (PAX6) located on chromosome 11p13 [1-3]. Iris hypoplasia
is the most obvious sign, but a broad spectrum of disorders
can manifest [2-4]. Many patients have corneal opacities,
cataracts, nystagmus, and foveal and optic nerve hypoplasia.
Aniridia typically causes severe visual impairment; the major
causative factor of this condition is foveal hypoplasia [5].
The  incidence  of  congenital  aniridia  ranges  from
1:64,000 to 1:96,000 [5]. In two-thirds of the cases, it is
inherited  in  an  autosomal  dominant  fashion  with  almost
complete  penetrance  and  variable  expressivity;  and  the
remaining one-third of the cases are sporadic [1,6,7]. Some
sporadic cases have a risk of developing Wilms tumor as a
part  of  WAGR  (Wilms  tumor,  aniridia,  genitourinary
abnormalities, and mental retardation; OMIM 194072), which
is caused by deletion of both PAX6 and Wilms’ tumor gene
(WT1) in the 11p13 region.
PAX6 was isolated as a candidate gene for aniridia by
positional cloning in 1991 [8]. Heterozygous mutations are
found  in  about  40%–80%  of  all  non-syndromic  aniridia
patients  [1,9-11].  Numerous  PAX6  mutations  have  been
detected in aniridia patients (Online Human PAX6 Allelic
Database), and premature termination of the PAX6 protein is
the most frequent type of mutation [11].
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Although about 60 cases of congenital aniridia have been
reported in Korea since the first report in 1977, little is known
about the molecular characterization of congenital aniridia in
Koreans  [12-15].  Here,  we  analyzed  PAX6  in  22  Korean
aniridic patients and identified the genetic aberrations and
genotype-phenotype correlations.
METHODS
This study was approved by the Ethics Committee of Seoul
St.  Mary’s  Hospital,  The  Catholic  University  of  Korea
(KC11RISI0722). Informed consent was obtained from the
patients.
We evaluated 22 patients in 18 unrelated aniridia families
in Seoul St.Mary’s Hospital. The age, gender, visual acuity,
family history, and previous ocular history of the patients were
recorded.  Thorough  ocular  examinations  were  performed,
including best-corrected visual acuity (BCVA), intraocular
pressure  (IOP),  and  refractive  measurement  and  slit  lamp
biomicroscopy  of  the  anterior  segment  and  fundus.  After
receiving informed consent, blood samples were collected
from all patients for DNA extraction and PAX6 analysis.
Genomic  DNA  was  isolated  from  peripheral  blood
leukocytes  with  the  QIAmp  DNA  Mini  Kit  (Qiagen,
Hamburg,  Germany).  The  DNA  was  quantified
spectrophotometrically  using  a  ND-1000  (Nanodrop
Technologies Inc., Wilmington, DE). All 14 exons (including
an alternatively spliced exon 5a) of PAX6 were amplified
using the primers as previously described (Table 1) [10]. For
all amplicons, the genomic DNA was denatured at 95 °C for
5 min followed by 35 cycles of denaturation at 95 °C for 30
s, annealing at 60 °C for 30 s, extension at 72 °C for 1 min,
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488and final extension at 72 for 5 min. The PCR products were
examined by agarose gel (1.5%) electrophoresis followed by
staining the gel in ethidium bromide (0.5 μg/ml), which then
was  visualized  under  ultraviolet  (UV)  light  in  a  gel
documentation system (Gel Doc 1000; Biorad, Hercules, CA).
PCR amplicons were bidirectionally sequenced with the Big
Dye  terminator  v3.1  cycle  sequencing  kit  (Applied
Biosystems, Foster City, CA) using the ABI PRISM 3100
Genetic  Analyzer  (Applied  Biosystems).  RefSeq  ID:
NM_000280.3 was used for cDNA nucleotide numbering.
RESULTS
Ocular phenotypes: Table 2 shows the ocular phenotypes of
22 patients in 18 unrelated families tested. The male/female
ratio was 0.59. The percentage of sporadic cases was 36.4%.
The mean age of the patients was 19.4±14.7 years. Total
aniridia was demonstrated in 20 patients and partial aniridia
in  2  patients  (patients  6-1  and  17).  Glaucoma,  cataracts,
keratopathy above grade II, and foveal hypoplasia were also
observed in addition to iris aplasia in the patients, as detailed
below. Nephroblastoma did not develop during the follow-up
period.
Glaucoma was observed in 7 of 22 patients (31.8%). Six
patients could maintain IOP within the normal range with
topical anti-glaucoma medications, but one female (patient
12)  required  surgical  treatment  with  Ahmed  valve
implantation in her left eye at 12 years old.
Cataracts were seen in 18 of 22 patients (81.8%), and 6
had received cataract surgery. Congenital corneal opacity was
observed in two children (patients 2 and 14), who required
penetrating  keratoplasty.  A  fundus  examination  was
performed in 20 patients who did not have severe corneal or
lens opacity. Foveal hypoplasia, defined as the absence of a
foveal reflex, was found in 17 patients (85%).
Genetic analysis of PAX6: The patients’ molecular findings
are summarized in Table 3. Fourteen different mutations were
detected in 16 of 18 unrelated families (88.9%). We found
four  novel  mutations,  including  c.87_90dupTGTA,  c.
464delG, c.642A>C, and c.658G>T, in addition to 10 known
mutations: c.11–2A>G, c.19G>T, c.301delG, c.317T>A, c.
524–2A>G,  c.607C>T  (n=3),  c.718C>T,  c.901C>T,  c.
949C>T (n=2), and c.1183+2T>C [9,16-26].
The  types  of  mutations  were  as  follows:  11  single
nucleotide  substitutions,  including  1  missense  mutation
TABLE 1. LIST OF PRIMERS USED TO PERFORM AMPLIFICATION AND SEQUENCING OF THE 14 PAX6 EXONS.
PAX6 gene Primer sequences for PAX6 (5′→3′) Tm (°C)
Exon 1 F-CTCATTTCCCGCTCTGGTTC 56
  R-AAGAGTGTGGGTGAGGAAGT  
Exon 2 F-TTATCTCTCACTCTCCAGCC 56
  R-AAGCGAGAAGAAAGAAGCGG  
Exon 3 F-TCAGAGAGCCCATCGACGTAT 56
  R-CTGTTTGTGGGTTTTGAGCC  
Exon 4 F-TTGGGAGTTCAGGCCTACCT 56
  R-GAAGTCCCAGAAAGACCAGA  
Exon 5 F-CCTCTTCACTCTGCTCTCTT 56
  R-ATGAAGAGAGGGCGTTGAGA  
Exon 5a F-TGAAAGTATCATCATATTTGTAG 50
  R-GGGAAGTGGACAGAAAACCA  
Exon 6 F-GTGGTTTTCTGTCCACTTCC 56
  R-AGGAGAGAGCATTGGGCTTA  
Exon 7 F-CAGGAGACACTACCATTTGG 56
  R-ATGCACATATGGAGAGCTGC  
Exon 8 F-GGGAATGTTTTGGTGAGGCT 56
  R-CAAAGGGCCCTGGCTAAATT  
Exon 9 F-GTAGTTCTGGCACAATATGG 54
  R-GTACTCTGTACAAGCACCTC  
Exon 10 F-GTAGACACAGTGCTAACCTG 56
  R-CCCGGAGCAAACAGGTTTAA  
Exon 11 F-TTAAACCTGTTTGCTCCGGG 56
  R-TTATGCAGGCCACCACCAGC  
Exon 12 F-GCTGTGTGATGTGTTCCTCA 56
  R-TGCAGCCTGCAGAAACAGTG  
Exon 13 F-CATGTCTGTTTCTCAAAGGGA 54
  R-GAACAATTAACTTTTGCTGGCC  
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490(7.1%),  7  nonsense  mutations  (50.0%),  and  3  intronic
mutations that lead to splicing errors (21.4%), in addition to
3 indel mutations that resulted in frameshifts (21.4%).
The DNA-binding domains (DBDs) of the PAX6 protein
were composed of the 128 amino acid paired domain (PD) and
the 61 amino acid homeodomain (HD) separated by a linker
region  (LNK).  The  proline-,  serine-,  and  threonine-rich
transregulatory (PST) domain in the COOH-terminal region
was composed of 152 amino acids. In this study, 5 kinds of
mutations  (35.7%)  occurred  in  the  PD,  and  3  kinds  of
mutations  (21.4%)  occurred  in  the  LNK,  HD,  and  PST
domains. Relatively fewer mutations have been detected in
the PST domain considering its long size.
Four novel mutations were detected in this study (Table
3,  Figure  1).  Patient  3  showed  the  c.87_90dupTGTA
(p.Glu31Cysfs*26) mutation in exon 5 within the PD, which
resulted in a premature termination due to the frame-shift.
Patients 6–1 (mother) and 6–2 (son) possessed a 1-bp deletion,
c.464delG (p.Ser155Thrfs*52), in exon 7, which causes a
frameshift and premature termination of translation in the
LNK domain of the PAX6 protein. Patient 10 was 3 year-old
male  and  had  a  novel  missense  mutation,  c.642A>C
(p.Arg214Ser), in exon 8 within the HD. This mutation was
predicted to be not tolerable by SIFT analysis and possibly
damaging  by  PolyPhen  analysis.  This  child  had  a  severe
clinical manifestation of aniridia with marked corneal opacity
and  increased  IOP  in  both  eyes.  This  mutation  was  not
detected in his unaffected mother. Patient 11 showed a novel
nonsense mutation, c.658G>T (p.Glu220*), in exon 8, which
results in premature termination within the LNK domain.
Single  nucleotide  variation  (SNV)  c.766–12C>T
(rs667773) was detected in 3 patients in 2 probands (7–1, 7–
2,  10)  who  represented  c.524–2A>G  and  c.642A>C,
respectively.
Genotype-phenotype  correlation:  Ophthalmic  and  genetic
findings  exhibited  inter-  and  intrafamilial  phenotypic
variabilities of the disease. Patient 1–2 had bilateral congenital
corneal  opacities  presumed  to  be  accompanying  Peters
anomaly, which were not observed in her mother (Patient 1–
1) with the same splicing error mutation (c.11–2A>G). In the
family with the c.464delG mutation (Patients 6–1 and 6–2),
one showed complete aniridia, and the other showed partial
aniridia. Patient 8–2 had juvenile onset glaucoma in both eyes,
which was not detected in Patients 8–1 and 9 with the same
nonsense mutation (c.607C>T).
We did not find any phenotypic differences according to
the location of the identified genotype. Nineteen patients had
total  aniridia  irrespective  of  the  domain  of  identified
mutations,  except  for  Patient  6–1  with  the  LNK  domain
frameshift mutation. The ocular phenotypes in patients with
three truncating mutations in the PST domains, which retained
the intact DNA-binding domains, were comparable to that
with mutations within the PD and HD domains.
TABLE 3. MOLECULAR FINDINGS IN KOREAN PATIENTS WITH CONGENITAL ANIRIDIA.
Case No Mutation Exon/Intron Domain mRNA/protein effect
1-1 c.11-2A>G Intron 4 PD Splicing error
1-2 c.11-2A>G Intron 4 PD Splicing error
2 c.19G>T Exon 5 PD p.Gly7*
3 c.87_90dup TGTA† Exon 5 PD p.Glu31Cysfs*26
4 c.301delG Exon 6 PD p.Glu101Lysfs*23
5 c.317T>A Exon 6 PD p.L106*
6-1 c.464delG† Exon 7 LNK p.Ser155Thrfs*52
6-2 c.464delG† Exon 7 LNK p.Ser155Thrfs*52
7-1 c.524-2A>G Intron 7 LNK Splicing error
7-2 c.524-2A>G Intron 7 LNK Splicing error
8-1 c.607C>T Exon 8 LNK p.Arg203*
8-2 c.607C>T Exon 8 LNK p.Arg203*
9 c.607C>T Exon 8 LNK p.Arg203*
10 c.642A>C† Exon 8 HD p.Arg214Ser
11 c.658G>T† Exon 8 HD p.Glu220*
12 c.718C>T Exon 9 HD p.Arg240*
13 c.901C>T exon10 PST p.Gln310*
14 c.949C>T Exon 11 PST p.Arg317*
15 c.949C>T Exon 11 PST p.Arg317*
16 c.1183+2T>C Intron 12 PST Splicing error
17 Not detected      
18 Not detected      
          A mark with † indicates the four novel mutations identified in this study.
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491DISCUSSION
In this report, we described PAX6 mutations in 22 Korean
aniridia patients from 18 unrelated families. The mutation
detection rate was 88.9% (16/18). The mutation spectrum of
PAX6 in aniridia was highly biased, as 92.9% of identified
mutations included 7 nonsense mutations (50.0%), 3 splicing
errors (21.4%), 2 deletions (14.3%), and 1 insertion (7.1%),
leading to the premature truncation of the protein and one
missense mutation inducing an amino acid change in the HD
domain. Interestingly, 4 novel mutations were identified in
this  study,  including  3  mutations  (c.87_90dupTGTA,  c.
464delG, and c.658G>T) leading to the premature termination
of the PAX6 protein and one missense mutation (c.642A>C).
The  phenotype  of  aniridia  could  be  explained  by  the
haploinsufficiency of the PAX6 protein, in which the mutated
PAX6 protein does not have any transcriptional activity and
the remaining single normal copy of PAX6 is not enough to
produce  a  sufficient  threshold  level  of  biologically  active
PAX6 protein to initiate the transcription of its target genes
[11,27,28]. A critical dose of PAX6 protein is required to
initiate the transcription of its downstream target genes for
normal  eye  development  [28].  Nonsense-mediated  decay,
which is the process in which mRNAs containing premature
termination codons are degraded before they produce large
amounts  of  truncated  proteins,  is  relevant  to  the
pathomechanism  of  aniridia  because  the  major  mutations
detected in aniridia are truncations. Haploinsufficiency in the
mutants in the COOH-terminal half of the PAX6 protein could
be explained by dominant-negative effects, which could be
caused by competition for DNA-binding between truncated
PAX6 proteins and wild-type PAX6 proteins. Some truncated
mutants  have  3–5  fold  higher  affinities  to  various  DNA
binding sites when compared with the wild-type PAX6 [27].
The  clinical  manifestations  associated  with  aniridia
express variable phenotypes. We did not find any phenotypic
differences  according  to  the  location  of  the  identified
genotypes. Our results also exhibited interfamilial (Patients
8–2 and 9) and intrafamilial (Patients 1–1 and 1–2, Patients
6–1  and  6–2,  and  Patients  8–1  and  8–2)  phenotypic
variabilities of the disease. Atchaneeyasakul et al.  reported
that  the  total  aniridia  phenotype  was  associated  with
mutations at the COOH-terminus, whereas partial aniridia
patients  carried  mutations  that  resulted  in  a  loss  of  the
homeodomain with or without a loss of the paired domain
[29]. However, our results are not consistent with that finding.
Total aniridia was observed in 19 patients irrespective of the
domain of identified mutations, except for patient 6–1 with
the  frameshift  mutation  within  the  LNK.  The  reason  for
variable  phenotypes  among  individuals  with  the  same
mutation  is  unclear.  The  variable  expressivity  could  be
explained by subtle differences in PAX6 protein levels and
the  ratio  of  mutant  to  wild  type  PAX6  protein  or  the
Figure  1.  Four  novel  PAX6  mutations  were  identified  in  this  study.  A-D:  Sequencing  chromatograms  of  c.658G>T,  c.642A>C,  c.
87_90dupTGTA, and c.464delG, respectively.
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492interactions with other factors [27]. Mutations behind the HD
could  potentially  lead  to  more  severe  phenotypes  than
truncating mutations within the DNA-binding domains, such
as the PD and HD [11,28]. Generally, the PAX6 missense
mutation occurs less frequently in aniridia and has a tendency
to be associated with milder phenotypes [18,30]. A PAX6
protein with an amino acid substitution could still retain some
residual activity and result in partial haploinsufficiency. Some
missense mutations might have the potential to impair the
proper  folding  of  the  PAX6  protein  and  compromise  the
normal three dimensional structure. In our 3-year old male
(Patient 10) carrying the novel missense mutation c.642A>C
(p.Arg214Ser), other factors than the mutated PAX6 protein
might contribute to his severe phenotype.
Accodring  to  the  PAX6  mutation  database,  the  most
frequent PAX6 mutations in aniridia are c.607C>T, c.718C>T,
c.949C>T,  and  c.1267dupT  (Online  Human  PAX6  Allele
Database)  [9,11].  The  former  three  muations  were  also
identified  in  this  study.  The  distribution  of  the  identified
mutations was as follows: 35.7% in the PD, 21.4% in the LNK,
21.4% in the HD, and 21.4% in the PST domains. Definite
mutational hot spots were not observed in our study. In two
patients, a PAX6 mutation was not identified with direct DNA
sequencing throughout the whole gene. Exon deletions and
deletions  of  control  regions  can  be  the  cause  of  isolated
aniridia, so that tests used to identify gene copy number, such
as  quantitative  PCR,  mutiplex  ligation-dependent  probe
amplification  (MLPA),  and  array  comparative  genomic
hybridization, may be helpful to clarify such cases.
Generally, it is recommended to perform several analyses
in anridia to obtain the maximum detection yield, as aniridia
could  be  caused  by  different  type  of  genetic  aberrations.
Chromosomal rearrangement and deletion can be detected by
karyotype analysis espcially in the cases of WAGR or the
aniridia  patients  presenting  other  malformation  [24].
Fluorescence  in  situ  hybridization  and  MLPA  can  detect
cryptic deletion of PAX6 effectively [24,31]. Detection of
PAX6  mutations  was  performed  using  direct  sequencing
method  combined  with  or  without  mutation  detection
screening tools such as DHPLC (denaturing high performance
liquid chromatography) or SSCP (single-strand conformation
polymorphism). Mutation detection rate by direct sequencing
of PAX6 was variable as follows; 47% (18/38) in Chinese
[32], 49% (34/70) in Caucasian [31], 30% (9/30) in Mexican
[9],  and  67%  (4/6)  in  Thai  patients  [29].  To  our  best
knowledge, our PAX6 mutation detection rate of 88.9% is the
one of highest rates by single test alone. One of the estimated
reason of our high mutation detection rate is the characteristics
of  patients  included  in  this  study.  Most  of  patients  had
clinically definite non-syndromic aniridia with total absence
of iris (20/22). The other possible reason to improve detection
rate  is  that  we  performed  bidirectional  sequencing  in  all
samples  because  the  mutations  in  aniridia  patients  were
distributed throughout the whole exon and intron of PAX6.
Based  on  our  result,  the  bidirectional  DNA  sequencing
including whole exon and intron-exon boundary of PAX6
could  be  recommended  as  the  first  screening  test  for  the
molecular confirmation of aniridia, especially when it is not
combined  with  other  systemic  abnomalities  such  as  renal
tumor, genitourinary abnormalities, and mental retardation.
In conclusion, most of the mutations identified in Korean
aniridia patients lead to the premature truncation of the PAX6
protein,  supporting  that  haploinsufficiency  of  the  PAX6
protein causes the classic aniridia phenotype. Also, we found
four novel PAX6 mutations associated with aniridia.
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